Evidence map›Paper›PMID 28622623›Full record

Trial reportLeukemia research2017

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.

Srdan Verstovsek, Stephane Courby, Martin Griesshammer, Ruben A Mesa, Carrie Baker Brachmann, Jun Kawashima, Julia D Maltzman, Lixin Shao, Yan Xin, Daniel Huang and 1 more

Open access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Cardiac complications of cancer therapies.Advances in cancer research · 2022
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Srdan VerstovsekThe University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: kjnewber@mdanderson.org.
Stephane CourbyCentre Hospitalier Universitaire de Grenoble, Grenoble, France.
Martin GriesshammerJohannes Wesling Klinikum Minden, University of Bochum, Germany.
Ruben A MesaMayo Clinic, Scottsdale, AZ, USA.
Carrie Baker BrachmannGilead Sciences, Inc., Foster City, CA, USA.
Jun KawashimaGilead Sciences, Inc., Foster City, CA, USA.
Julia D MaltzmanGilead Sciences, Inc., Foster City, CA, USA.
Lixin ShaoGilead Sciences, Inc., Foster City, CA, USA.
Yan XinGilead Sciences, Inc., Foster City, CA, USA.
Daniel HuangThe Oncology Institute of Hope and Innovation, Santa Ana, CA, USA.
Ashish BajelDepartment of Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Victoria, Australia.
Gilead Sciences (United States) · USCentre Hospitalier Universitaire de Grenoble · FRJohannes Wesling Klinikum Minden · DEMayo Clinic in Arizona · USOncology Institute of Hope and Innovation · USThe Royal Melbourne Hospital · AUThe University of Texas MD Anderson Cancer Center · US

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
NCI NIH HHS P30 CA054174
6 · The paper itself

Abstract

Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients with primary and secondary myelofibrosis. This phase 2, open-label, randomized study evaluated the efficacy and safety of oral once-daily momelotinib (100mg and 200mg) for the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). The primary endpoint for PV was overall response rate (ORR), defined as the proportion of patients with hematocrit <45%, white blood cell count <10×10

Indexed as

AdultAgedAged, 80 and overBenzamidesFemaleHumansJanus Kinase 1Janus Kinase 2MaleMiddle AgedPolycythemia VeraProtein Kinase InhibitorsPyrimidinesThrombocythemia, EssentialTreatment OutcomeBenzamidesJAK1 protein, humanJAK2 protein, humanJanus Kinase 1Janus Kinase 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideProtein Kinase InhibitorsPyrimidinesEssential thrombocythemiaMomelotinibPhase 2 studyPolycythemia vera

Identifiers

PMID28622623
PMCPMC8170698
OpenAlexW2617895748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.